First Wave To Merge With ImmunogenX With Focus On Celiac Disease

 
• By Joseph Haas

Troubled by recent clinical disappointments, First Wave will combine with ImmunogenX to focus on that company’s Phase III-ready enzyme replacement therapy for celiac disease. A deep-pocketed partner waits in the wings.

Gluten-free
First Wave merges with ImmunogenX with a goal of producing the first celiac disease drug • Source: Shutterstock

More from Deals

More from Business